Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development

被引:103
作者
Nishimura, Y
Igarashi, T
Haigwood, NL
Sadjadpour, R
Donau, OK
Buckler, C
Plishka, RJ
Buckler-White, A
Martin, MA
机构
[1] NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA
[2] Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA
[3] Seattle Biomed Res Inst, Viral Vaccines Program, Seattle, WA 98109 USA
关键词
D O I
10.1073/pnas.2436476100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Passive transfer of high-titered antiviral neutralizing IgG, known to confer sterilizing immunity in pig-tailed monkeys, has been used to determine how soon after virus exposure neutralizing antibodies (NAbs) must be present to block a simian immunodeficiency virus (SIV)/HIV chimeric virus infection. Sterilizing protection was achieved in three of four macaques receiving neutralizing IgG 6 h after intravenous SIV/HIV chimeric virus inoculation as monitored by PCR analyses of and attempted virus isolations from plasma, peripheral blood mononuclear, cell, and lymph node specimens. In the fourth animal, the production of progeny virus was suppressed for >4 weeks. A delay in transferring NAbs until 24 h after virus challenge resulted in infection in two of two monkeys. These results suggest that even if a vaccine capable of eliciting broadly reactive NAbs against primary HIV-1 were at hand, the Abs generated must remain at, or rapidly achieve, high levels within a relatively short period after exposure to virus to prevent the establishment of a primate lentivirus infection.
引用
收藏
页码:15131 / 15136
页数:6
相关论文
共 59 条
[21]   Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1 [J].
Hezareh, M ;
Hessell, AJ ;
Jensen, RC ;
van de Winkel, JGJ ;
Parren, PWHI .
JOURNAL OF VIROLOGY, 2001, 75 (24) :12161-12168
[22]   Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma [J].
Igarashi, T ;
Brown, C ;
Azadegan, A ;
Haigwood, N ;
Dimitrov, D ;
Martin, MA ;
Shibata, R .
NATURE MEDICINE, 1999, 5 (02) :211-216
[23]   Antiviral B cell memory in the absence of mature follicular dendritic cell networks and classical germinal centers in TNFR1-/- mice [J].
Karrer, U ;
López-Macías, C ;
Oxenius, A ;
Odermatt, B ;
Bachmann, MF ;
Kalinke, U ;
Bluethmann, H ;
Hengartner, H ;
Zinkernagel, RM .
JOURNAL OF IMMUNOLOGY, 2000, 164 (02) :768-778
[24]   Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement [J].
Kostrikis, LG ;
Cao, YZ ;
Ngai, H ;
Moore, JP ;
Ho, DD .
JOURNAL OF VIROLOGY, 1996, 70 (01) :445-458
[25]   Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies [J].
Mascola, JR ;
Lewis, MG ;
VanCott, TC ;
Stiegler, G ;
Katinger, H ;
Seaman, M ;
Beaudry, K ;
Barouch, DH ;
Korioth-Schmitz, B ;
Krivulka, G ;
Sambor, A ;
Welcher, B ;
Douek, DC ;
Montefiori, DC ;
Shiver, JW ;
Poignard, P ;
Burton, DR ;
Letvin, NL .
JOURNAL OF VIROLOGY, 2003, 77 (19) :10348-10356
[26]   Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies [J].
Mascola, JR ;
Lewis, MG ;
Stiegler, G ;
Harris, D ;
VanCott, TC ;
Hayes, D ;
Louder, MK ;
Brown, CR ;
Sapan, CV ;
Frankel, SS ;
Lu, YC ;
Robb, ML ;
Katinger, H ;
Birx, DL .
JOURNAL OF VIROLOGY, 1999, 73 (05) :4009-4018
[27]   Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies [J].
Mascola, JR ;
Stiegler, G ;
VanCott, TC ;
Katinger, H ;
Carpenter, CB ;
Hanson, CE ;
Beary, H ;
Hayes, D ;
Frankel, SS ;
Birx, DL ;
Lewis, MG .
NATURE MEDICINE, 2000, 6 (02) :207-210
[28]   RESTRICTED NEUTRALIZATION OF DIVERGENT HUMAN T-LYMPHOTROPIC VIRUS TYPE-III ISOLATES BY ANTIBODIES TO THE MAJOR ENVELOPE GLYCOPROTEIN [J].
MATTHEWS, TJ ;
LANGLOIS, AJ ;
ROBEY, WG ;
CHANG, NT ;
GALLO, RC ;
FISCHINGER, PJ ;
BOLOGNESI, DP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (24) :9709-9713
[29]   A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection [J].
McElrath, MJ ;
Corey, L ;
Montefiori, D ;
Wolff, M ;
Schwartz, D ;
Keefer, M ;
Belshe, R ;
Graham, BS ;
Matthews, T ;
Wright, P ;
Gorse, G ;
Dolin, R ;
Berman, P ;
Francis, D ;
Duliege, AM ;
Bolognesi, D ;
Stablein, D ;
Ketter, N ;
Fast, P .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (09) :907-919
[30]   Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals [J].
Moog, C ;
Fleury, HJA ;
Pellegrin, I ;
Kirn, A ;
Aubertin, AM .
JOURNAL OF VIROLOGY, 1997, 71 (05) :3734-3741